跳转至内容
Merck
CN

N165

Sigma-Aldrich

Naloxone benzoylhydrazone

solid

别名:

[(5α)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-ylidene]hydrazide benzoic acid

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C26H27N3O4
化学文摘社编号:
分子量:
445.51
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

表单

solid

质量水平

药品控制

regulated under CDSA - not available from Sigma-Aldrich Canada

颜色

yellow

溶解性

DMSO: soluble
H2O: soluble (with the addition of 0.1 N HCl)
ethanol: soluble

储存温度

−20°C

SMILES字符串

[H][C@@]12Oc3c(O)ccc4C[C@H]5N(CC[C@@]1(c34)[C@@]5(O)CC\C2=N/NC(=O)c6ccccc6)CC=C

InChI

1S/C26H27N3O4/c1-2-13-29-14-12-25-21-17-8-9-19(30)22(21)33-23(25)18(10-11-26(25,32)20(29)15-17)27-28-24(31)16-6-4-3-5-7-16/h2-9,20,23,30,32H,1,10-15H2,(H,28,31)/b27-18+/t20-,23+,25+,26-/m1/s1

InChI key

AKXCFAYOTIEFOH-XTNAHFASSA-N

基因信息

生化/生理作用

Agonist for κ3 opioid receptors; antagonist for ORL1 and μ opioid receptors.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

D Ichikawa et al.
Neuroreport, 12(8), 1757-1761 (2001-06-21)
J-113397 (1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one) is a recently developed antagonist of the opioid receptor-like 1 (ORL1) receptor. We compared the in vitro functional profile J-113397 on [35S]guanosine 5'-O-(gamma-thio)triphosphate (GTPgammaS) binding to mouse brain with that of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 and naloxone benzoylhydrazone (NalBzoH). J-113397 antagonized
Veronica Cox et al.
Neuropharmacology, 48(2), 228-235 (2005-02-08)
Naloxone benzoylhydrazone (NalBzoH) is a ligand used to study opioid receptors. It has been suggested to act at a novel kappa3 receptor but also appears to bind to classical opioid receptors, and possibly the ORL1 receptor. We have used opioid
Eve Salonius et al.
Journal of cellular physiology, 235(4), 3497-3507 (2019-09-26)
Cell therapy combined with biomaterial scaffolds is used to treat cartilage defects. We hypothesized that chondrogenic differentiation bone marrow-derived mesenchymal stem cells (BM-MSCs) in three-dimensional biomaterial scaffolds would initiate cartilaginous matrix deposition and prepare the construct for cartilage regeneration in
J P Mathis et al.
Synapse (New York, N.Y.), 34(3), 181-186 (1999-10-19)
The presence of pairs of basic amino acids within the orphanin FQ/Nociceptin (OFQ/N) sequence has raised the possibility that truncated versions of the peptide might be physiologically important. OFQ/N(1-11) is pharmacologically active in mice, despite its poor affinity in binding
Pierluigi Onali et al.
British journal of pharmacology, 143(5), 638-648 (2004-09-29)
1 Naloxone benzoylhydrazone (NalBzoH) has initially been developed as an agonist of the pharmacologically defined kappa3-opioid receptor and has recently been employed as an antagonist at the opioid receptor-like (ORL1) receptor. In the present study, we investigated the ability of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持